Survival Benefit With Concomitant Oral Platelet Therapy After Coronary Angiography and Before Ad Hoc Percutaneous Coronary Intervention
- Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Pierangeli, S. S.; Erkan, D. // Lupus;Apr2010, Vol. 19 Issue 4, p475
Persistently positive antiphospholipid antibodies in association with thromboses and/or pregnancy morbidity is the hallmark of the antiphospholipid syndrome. The management of antiphospholipid antibody-positive patients has been focused on utilizing anti-thrombotic medications such as heparin or...
- Platelet glycoprotein IbÎ± polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease. Jilma-Stohlawetz, Petra; Jilma, Bernd; Mannhalter, Christine; Bencur, Peter; Pabinger, Ingrid; Vormittag, Rainer; Dunkler, Daniela; Panzer, Simon // Annals of Hematology;Oct2007, Vol. 86 Issue 10, p719
Lupus anticoagulants (LA) are a surrogate marker for the risk of thromboembolic disease (TE). However, not all individuals with LA acquire TE, and it is desirable to distinguish those at risk for TE from those without. Platelets polymorphisms may contribute to the risk of TE, mainly those of...
- Balancing the Expression and Production of a Heterodimeric Protein: Recombinant Agkisacutacin as a Novel Antithrombotic Drug Candidate. Guo, Yugang; Ma, Jiajia; Sun, Jie; Tian, Zhigang; Xiao, Weihua; Wu, Jing; Chen, Wei; Shao, Changsheng; Zhao, Lei; Jia, Hao; Li, Rui; Zhong, Yongjun; Fang, Fang; Wang, Dong; Qian, Fang; Dai, Xiangrong; Zhang, Guohui; Xiaoyi Li, Benjamin // Scientific Reports;7/10/2015, p11730
Agkisacucetin extracted from the venom of Agkistrodon acutus has been demonstrated to be a promising antithrombotic drug candidate in clinical studies due to its function as a novel platelet membrane glycoprotein (GP) Ib inhibitor. Agkisacucetin is a heterodimeric protein composed of Î±- and...
- Glanzmann's thrombasthenia. // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p956
An encyclopedia entry for "Glanzmann's thrombasthenia," which refers to a rare autosomal recessive abnormality of platelet glycoprotein IIb-IIIa that is characterized by easy bruising and epostaxis that may sometimes requires blood transfusions, is presented.
- Short- and Long-Term Results of Abciximab Versus Aspirin in Conjunction with Thrombyolysis for Patients with Peripheral Occlusive Arterial Disease and Arterial Thrombosis. Schweizer, Johannes // Angiology;Nov2000, Vol. 51 Issue 11, p913
Evaluates the use of the platelet glycoprotein GP IIb/IIIa receptor antagonist abciximab versus aspirin in thrombolysis in patients with arterial thrombosis. Criteria for measuring primary efficacy; Reduction of the rates of rehospitalization; Decrease in the duration of lysis.
- Review: Platelet glycoprotein IIb/IIIa blockers for PCI or acute coronary syndromes reduce death and MI but increase bleeding. Bates, Eric R. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p41
Focuses on a study which investigated the effect of platelet glycoprotein IIb/IIIa blockers for percutaneous coronary intervention or acute coronary syndromes. Methodology of the study; Results; Comments on the outcome of the study.
- Inhibition of Human Platelet Function in Vivo with a Monoclonal Anti-body. Coller, Barry S.; Scudder, Lesley E.; Berger, Harvey J.; Iuliucci, John D. // Annals of Internal Medicine;10/15/88, Vol. 109 Issue 8, p635
Demonstrates that the abolition of platelet function mediated by the glycoprotein IIb/IIIa receptor can be achieved in human by in vivo infusion of 7E2-F(ab') [sub2] without immediate hemodynamic or hemorrhagic toxicity. Information on the F(ab') [sub2] fragment of a monoclonal antibody to the...
- Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Current Concepts and Future Directions. Ferguson, J.J.; Zaqqa, M. // Drugs;Dec1999, Vol. 58 Issue 6, p965
Platelets play a key role in the development of thrombosis. Glycoprotein (GP) IIb/IIIa antagonists are a new class of potent drugs that profoundly inhibit platelet function by blocking the key receptor involved in platelet aggregation. Several antiplatelet agents with varying characteristics...
- Impact of Thrombophilic Genetic Factors on Pulmonary Embolism: Early Onset and Recurrent Incidences. Ivanov, Petar; Komsa-Penkova, Regina; Kovacheva, Katia; Ivanov, Yavor; Stoyanova, Angelina; Ivanov, Ivan; Pavlov, Plamen; Glogovska, Pavlina; Nojarov, Venzislav // Lung;Jan/Feb2008, Vol. 186 Issue 1, p27
The importance of genetic thrombophilic factors in the development of venous thromboembolism has been increasingly recognized. Factor V Leiden (FVL), prothrombin gene mutation G20210A (FII G20210), genetic variant C677T of the methylentetrahydrofolate reductase (MTHFR), as well as the...